trial

Clinical Estradiol Trial in Women With Schizophrenia

NCTId NCT00206570
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 100 (estimated)
Sponsored by Bayside Health
Primary completion 2004-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2001-01
Primary completion
2004-12
Eligibility
FEMALE · 18 Years · 45 Years

Interventions & indications

Drugs
Estradiol

Sponsors

Bayside HealthLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
Stanley Medical Research InstituteCollaborator
National Health and Medical Research Council, AustraliaCollaborator

Investigators

1
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Linked catalysts

1
Clinical Estradiol Trial in Women With Schizophrenia — primary completion2004-12

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2
Primary Completion Date
2004-12
Status
COMPLETED
relationships
The graph out of here
drug
Estradiol
drug
lead_sponsor
Bayside Health
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Stanley Medical Research Institute
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHD
person